Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$70.95 +0.4%	$64.55	$47.86 ▼ $107.37	$3.90B	0.28	461,589 shs	534,969 shs
MRUS Merus	$61.44 +8.7%	$52.03	$33.19 ▼ $62.98	$4.25B	1	732,000 shs	1.34 million shs
NAGE Niagen Bioscience	$10.35 -10.0%	$12.01	$2.53 ▼ $14.69	$815.27M	2.14	894,009 shs	1.50 million shs
RNA Avidity Biosciences	$34.04 +1.5%	$30.76	$21.51 ▼ $56.00	$4.10B	0.91	1.41 million shs	2.78 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	+3.74%	+2.46%	+10.31%	+14.00%	+7.25%
MRUS Merus	+2.76%	+3.67%	+6.02%	+31.24%	-3.96%
NAGE Niagen Bioscience	+3.79%	-5.12%	-18.67%	+70.12%	+340.61%
RNA Avidity Biosciences	+5.77%	+7.23%	+12.52%	+25.77%	-28.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
ACLX Arcellx	2.5135 of 5 stars	3.5	2.0	3.1	2.5
MRUS Merus	1.9388 of 5 stars	3.6	1.0	2.1	2.5
NAGE Niagen Bioscience	1.6245 of 5 stars	3.5	0.0	3.2	0.0
RNA Avidity Biosciences	2.1711 of 5 stars	4.5	0.0	2.7	0.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.23	56.77% Upside
MRUS Merus	3.14	Buy	$84.64	37.75% Upside
NAGE Niagen Bioscience	3.00	Buy	$13.22	27.73% Upside
RNA Avidity Biosciences	3.06	Buy	$66.35	94.93% Upside

Current Analyst Ratings Breakdown

Latest NAGE, ACLX, MRUS, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	RNA Avidity Biosciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
7/10/2025	RNA Avidity Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$55.00
6/27/2025	RNA Avidity Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00
6/24/2025	RNA Avidity Biosciences	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
6/16/2025	ACLX Arcellx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00
6/11/2025	RNA Avidity Biosciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$65.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/10/2025	RNA Avidity Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $75.00
6/10/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$107.94M	36.22	N/A	N/A	$8.41 per share	8.44
MRUS Merus	$36.13M	117.69	N/A	N/A	$9.46 per share	6.49
NAGE Niagen Bioscience	$99.60M	8.19	$0.06 per share	187.32	$0.60 per share	17.25
RNA Avidity Biosciences	$8.93M	459.56	N/A	N/A	$11.94 per share	2.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$107.35M	-$2.99	0.00	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
NAGE Niagen Bioscience	$8.55M	$0.17	60.88	∞	N/A	13.07%	19.06%	12.20%	N/A
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)

Latest NAGE, ACLX, MRUS, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACLX Arcellx	-$1.03	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q2 2025	RNA Avidity Biosciences	-$0.93	N/A	N/A	N/A	$1.61 million	N/A
8/7/2025	Q1 2025	MRUS Merus	-$1.17	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.93	4.93
MRUS Merus	N/A	5.86	5.86
NAGE Niagen Bioscience	N/A	3.66	3.12
RNA Avidity Biosciences	N/A	16.91	16.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
MRUS Merus	96.14%
NAGE Niagen Bioscience	15.41%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
MRUS Merus	4.57%
NAGE Niagen Bioscience	9.39%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	71.37 million	N/A
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable

NAGE, ACLX, MRUS, and RNA Headlines

Recent News About These Companies

Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive

July 14 at 4:24 PM | seekingalpha.com

Avidity Biosciences (NASDAQ:RNA) Shares Gap Up - Here's Why

July 14 at 11:11 AM | marketbeat.com

Avidity Biosciences price target raised to $70 from $60 at Evercore ISI

July 12, 2025 | msn.com

Alps Advisors Inc. Has $2.58 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 12, 2025 | marketbeat.com

The Goldman Sachs Group Upgrades Avidity Biosciences (NASDAQ:RNA) to Buy

July 12, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. (RNA) Balance Sheet - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated by Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Boosts Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

July 6, 2025 | marketbeat.com

Avidity Biosciences, Inc. (RNA) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

7RNA : Expert Outlook: Avidity Biosciences Through The Eyes...

June 27, 2025 | benzinga.com

Avidity Biosciences (NASDAQ:RNA) Receives "Overweight" Rating from Cantor Fitzgerald

June 27, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA therapies stock faces pivotal year

June 26, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from Analysts

June 26, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Earns Outperform Rating from Analysts at Sanford C. Bernstein

June 24, 2025 | marketbeat.com

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

June 24, 2025 | investing.com

SG Americas Securities LLC Takes $516,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 23, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027

June 20, 2025 | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in Stock

June 19, 2025 | insidertrades.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 Shares

June 18, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Here's Why

June 17, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated at Wolfe Research

June 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
By Gabriel Osorio-Mazilli | June 25, 2025
View ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Tesla: 2 Plays Ahead of Next Week's Earnings Report
By Sam Quirke | July 15, 2025
View Tesla: 2 Plays Ahead of Next Week's Earnings Report
This Fund Manager Says You Should Get Out of Tesla and Apple—Now
By Brian O'Connell | July 16, 2025
View This Fund Manager Says You Should Get Out of Tesla and Apple—Now
Analysts Are All In on This Tech Stock—Why You Should Be, Too
By Nathan Reiff | July 1, 2025
View Analysts Are All In on This Tech Stock—Why You Should Be, Too
Will Dollar Tree Break Out After a New $2.5 Billion Buyback?
By Gabriel Osorio-Mazilli | July 15, 2025
View Will Dollar Tree Break Out After a New $2.5 Billion Buyback?

NAGE, ACLX, MRUS, and RNA Company Descriptions

Arcellx NASDAQ:ACLX

$70.95 +0.25 (+0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$70.94 -0.01 (-0.01%)

As of 05:11 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Merus NASDAQ:MRUS

$61.44 +4.93 (+8.72%)

Closing price 04:00 PM Eastern

Extended Trading

$61.44 0.00 (0.00%)

As of 07:25 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Niagen Bioscience NASDAQ:NAGE

$10.35 -1.15 (-10.00%)

As of 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Avidity Biosciences NASDAQ:RNA

$34.04 +0.51 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$34.22 +0.19 (+0.54%)

As of 07:59 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time